- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787082
Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension
A Randomized Trial of Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.
The investigators will enroll 40 PH patients over three years. 5 healthy participants will be enrolled as controls. Participants will receive a single dose of the study drug,:14N Sodium Nitrate(1000mg): standard sodium nitrate, and all will receive one dose of CLA 3g. CLA will be obtained from GNC (General Nutrition Corporation) and given once. Participants will be randomized to receive chlorhexidine gluconate 0.12% (15mL) or placebo to rinse their mouth with for 1 minute.
Oral samples will be collected pre- and post-chlorhexidine treatments and stool samples will be collected post-chlorhexidine treatment.
Right heart catheterization will be performed for clinical or research purposes.
The RHC done (in the last 5 years) that establishes inclusion is not the same RHC done as part of the study in most cases. If there is a strong suspicion of PH based on echocardiography in a patient who has not had a clinical RHC, the first hemodynamic measurements obtained in the clinical RHC will establish inclusion and the RHC study procedures will be performed following confirmation of inclusion.
Participants for whom the RHC done in the study is considered a clinical RHC will be participants who do have an additional follow up RHC scheduled.
Participants for whom the RHC done in the study is considered a research RHC will be those who do not have an additional follow RHC scheduled or who are considered healthy and have not had an RHC before.
Catheterization will generally be performed via the right internal jugular vein access with the assistance of fluoroscopy, if needed. Once the pulmonary arterial (PA) catheter has been placed in proper position, measured values will be obtained. The investigators often perform simultaneous measurement of right atrial pressure and distal pressure (PAP/PAWP) using two transducers in order to assess both pressures during vasodilator challenge, or other confrontational testing. An initial hemodynamic profile will be obtained.
With the right heart catheter still in place, participants will be randomized to either chlorhexidine mouthwash or placebo, then after 30 minutes, all will receive 14N oral nitrate and CLA. A repeat hemodynamic profile will be performed after two hours. Nitrate metabolites in plasma will be measured at time 0, 2, and 6 hrs after 14N nitrate dose. Urine nitrite and nitrate will be measured at 0 and 6 hours. Participants will be monitored with continuous pulse oximetry and EKG monitoring. Blood pressure measurements will be performed every 15 minutes during the catheterization. Pressure-volume loop and impedance analysis will be performed at the time of the right heart catheterization (RHC) using the micromanometer catheter technique to simultaneously measure RV pressure and pulmonary blood flow.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Cathy Kessinger
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 years of age or older
- Undergoing clinical right heart catheterization or had a RHC in past 5 years if in PH group
- Pulmonary Hypertension: hemodynamically defined by a mean PAP ≥ 25 mm Hg and have a PVR > 3 Woods units and normal cardiac index (>2.0 L/min/m2)
- Healthy Control group: no history of or active cardiac or pulmonary disease
- Ability to provide written informed consent
Exclusion Criteria:
- Use of systemic antibiotics and/or chlorhexidine mouthwash within the previous three months
- Use of immune suppression (chemotherapy, oral prednisone greater than 20mg per day, etc) with in the previous three months
- Use of phosphodiesterase-5 inhibitors (tadalafil, sildenafil, etc) within 7 days before study drug administration
- Current pregnancy or lactation
- Uncontrolled systemic hypertension based on repeated measurement of sitting systolic blood pressure >185 mm Hg or sitting diastolic blood pressure >110 mm Hg
- Has chronic renal insufficiency as defined by serum creatinine >3 mg/dL in the last 6 months or requiring dialytic support as reported in the medical record
- Known history of left ventricular ejection fraction < 40% by multiple gated acquisition scan (MUGA), angiography, or echocardiography
- History of atrial septostomy
- Repaired or unrepaired congenital heart disease
- Pericardial constriction
- Restrictive or constrictive cardiomyopathy
- Symptomatic coronary disease with demonstrable ischemia
- Addition or change in dosing of hormonal contraception medications (OCP, IUD, Depo-Provera) in the past 4 weeks.
- Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study
- Active participation in other research studies with investigational drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chlorhexidine Gluconate Mouthwash
rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18
mmol, oral
|
1,000 mg/11.18 mmol, oral
Other Names:
chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
Other Names:
|
Placebo Comparator: Placebo Mouthwash
rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18
mmol, oral
|
1,000 mg/11.18 mmol, oral
Other Names:
sterile water (15mL) mouth rinse for 1 minute
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Plasma Nitrate
Time Frame: At baseline and 2 hours post drug administration
|
At baseline and 2 hours post drug administration
|
Change in Urine Nitrate
Time Frame: At baseline and 2 hours post drug administration
|
At baseline and 2 hours post drug administration
|
Change in Plasma Nitrate
Time Frame: At baseline and 6 hours post drug administration
|
At baseline and 6 hours post drug administration
|
Change in Urine Nitrate
Time Frame: At baseline and 6 hours post drug administration
|
At baseline and 6 hours post drug administration
|
Change in Plasma Nitrate
Time Frame: At 2 hours post drug administration and 6 hours post drug administration
|
At 2 hours post drug administration and 6 hours post drug administration
|
Change in Urine Nitrate
Time Frame: At 2 hours post drug administration and 6 hours post drug administration
|
At 2 hours post drug administration and 6 hours post drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Pulmonary Vascular Resistance (PVR)
Time Frame: At baseline and 2 hours post drug administration
|
At baseline and 2 hours post drug administration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY19120104
- 5P01HL103455 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
BayerCompletedPrimary HypertensionChina
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
University of ZurichActive, not recruitingPulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Vascular DisorderSwitzerland
Clinical Trials on Nitrates
-
Universidad Católica San Antonio de MurciaCompleted
-
Ministry of Health, Saudi ArabiaUnknown
-
Indiana UniversityVanderbilt UniversityTerminatedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
-
Ain Shams UniversityRecruiting
-
University of TorontoSunnybrook Health Sciences Centre; Canadian Institutes of Health Research (CIHR) and other collaboratorsCompleted
-
University of Mississippi Medical CenterTerminatedVascular Function | Racial DisparityUnited States
-
University of CaraboboNorthern Metropolitan Hospital; Venezuelan Foundation of Heart Failure; Clinical...Completed
-
Gruppo Italiano Multidisciplinare per lo Studio...Completed
-
Alere San DiegoTerminatedHeart FailureUnited States, Netherlands, New Zealand, United Kingdom, Ireland, Sweden
-
Fondazione Policlinico Universitario Agostino Gemelli...IRCCS Policlinico S. Donato; Centro Cardiologico MonzinoRecruitingMyocardial Infarction With Non-Obstructive Coronary ArteriesItaly